Aerpio Therapeutics Initiates Phase 1b/2a Trial of AKB-9778 in Diabetic Macular Edema

Posted by on Dec 5, 2012 in Uncategorized |

Biotechnology company Aerpio Therapeutics has advanced its novel small molecule drug for diabetic macular edema (DME) into a Phase 1b/2a clinical trial (dose-range finding in patients). Aerpio’s lead compound, AKB-9778 affects the Ang/Tie pathway, an exciting and very promising target in diabetic macular edema.

Dr. Ng serves on the clinical advisory board of Aerpio Therapeutics.

For more information, please go to

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien